Background: This study aimed to compare the efficacy of two modes of delivery of diclofenac for the management of post-endodontic pain.
Materials And Methods: This study comprised 30 patients reporting to the department with pain in their teeth. Pain was assessed using the visual analog scale (VAS): group A (control group), group B (oral diclofenac), and group C (transdermal patch). A VAS was given to the patients in each group, and the severity of any pain was self-assessed by patients after 4 hrs, 8 hrs, 12 hrs, 24 hrs, and 48 hrs following the completion of treatment.
Results: A comparison between group oral and diclofenac transdermal patch was carried out. The pain frequency was measured at 4 hrs, 8 hrs, 12 hrs, 24 hrs, and 48 hrs postoperatively with values of 0.744, 0.035, 0.570, 0.060, and 0.508 and was statistically insignificant.
Conclusion: Preoperative analgesics play an important role in reducing post-endodontic pain. Transdermal patches containing diclofenac show a promising analgesic modality in managing endodontic pain.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10485447 | PMC |
| http://dx.doi.org/10.4103/jpbs.jpbs_119_23 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Basic Science and Pathogenesis.
Alzheimers Dement
December 2024
Neurophysiology Unit, Cardiac Electrophysiology Research and Training Center, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.
Background: Microglia play an important role in immune memory. Lipopolysaccharide (LPS) triggers immune memory and primes microglia, resulting in brain pathologies and brain dysfunction following a second stimulus (1, 2). An increase in the C1q/ PSD95 expressions within microglia and excessively synaptic pruning were observed in mouse model of Alzheimer's disease (3).
View Article and Find Full Text PDFBasic Science and Pathogenesis.
Alzheimers Dement
December 2024
University of Minnesota, Minneapolis, MN, USA.
Background: With the emerging role of the blood biomarkers in Alzheimer's Disease (AD) clinical practice and trials, it is crucial to identify and address factors influencing the concentrations of these biomarkers in circulation for enhanced clinical utility. We aim to assess the impact of lung function on plasma AD biomarker levels and elucidate the relationship between lung function and Alzheimer's Disease and Related Dementias (ADRD).
Method: We used the Peak Expiratory Flow (PEF), plasma biomarkers of AD (Amyloid beta 42/40 (Aβ42/40) ratio, phosphorylated-tau181 (p-tau181), Neurofilament light chain (NfL) and Glial fibrillary acidic protein (GFAP)) measured in the Health and Retirement Study (HRS) 2016 survey participants (n = 3801) and incident dementia (n = 142) over 4 years.
Basic Science and Pathogenesis.
Alzheimers Dement
December 2024
Indiana University School of Medicine, Indianapolis, IN, USA.
Background: APOE e4 has been used to evaluate the risk for Alzheimer's diseases (AD) but there exist other AD risk genes, and their effects can be collectively measured by polygenic risk scores (PRS). In this study, we sought to use both PRS (APOE excluded) and APOE e4 to evaluate the AD risk.
Method: The discovery dataset was meta-analysis of three large-scale European ancestry AD GWAS (Kunkle et al, 2019, the UK Biobank, and the FinnGen consortium).
Basic Science and Pathogenesis.
Alzheimers Dement
December 2024
University of Kentucky/Sanders-Brown Center on Aging, Lexington, KY, USA.
Background: The characterization of intercellular communication between peripheral immune cells and the central nervous system (CNS) are essential for understanding the brain's response to aging and disease states, such as Alzheimer's disease. MicroRNAs (miRNAs) constitute a class of small non-coding RNAs that play a crucial role in regulating various biological and pathological processes, including those related to immunity and inflammation. MiR-223-3p, residing on the X chromosome, is a pivotal miRNA involved in the inflammatory response, with its expression being enriched in macrophages/microglia.
View Article and Find Full Text PDFClinical Manifestations.
Alzheimers Dement
December 2024
Otsuka Pharmaceutical Development & Commercialization Inc., Princeton, NJ, USA.
Background: A reduction in the frequency of agitation behaviors is a clinically meaningful outcome among patients with agitation associated with dementia due to Alzheimer's disease. This post hoc analysis aimed to determine the percentage of patients treated with brexpiprazole who achieved sustained clinically meaningful response (CMR), over 12 and 24 weeks.
Method: Data for brexpiprazole 2 or 3 mg/day were obtained from two trials of patients with agitation associated with dementia due to Alzheimer's disease: a 12-week, randomized, double-blind, placebo-controlled trial (ClinicalTrials.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!